Roche is planning to create a translational research centre at the Alexandria Center for Life Science in New York City.
The creation of the centre follows the announcement last month that Roche will close its former US headquarters in Nutley, New Jersey, and means the pharma company will still have a base on the east coast of the US.
The new centre will employ around 240 people who will be responsible for leading the company's global early development programmes and clinical trials, as well as implementing translational research programmes focused on disease understanding and the development of new medicines.
The New York base could also make it easier to maintain relations with the Food and Drug Administration (FDA), which is also based on the east coast in Maryland, and support collaborations with Roche's US based partners, such as academic institutions and biotech companies.
The centre is expected to be ready by the fourth quarter of 2013, and is situated next to New York City's nine major academic medical centres.
“We looked at several great properties in New York and New Jersey and selected the Alexandria Center for Life Science for its unique location as well as the dynamic, vibrant, and thriving scientific atmosphere it offers,” said Dr Mike Burgess, acting global head, Roche Pharma research and early development.
Roche has an existing relationship with Alexandria Real Estate Equities, which owns the Centre, having a tenancy in San Francisco at the Alexandria Center for Science and Technology.
Other organisations based at the New York centre include Eli Lilly's oncology-focused subsidiary ImClone Systems, and Pfizer, which has its centres for therapeutic innovation located in the centre.
In addition, New York University's neuroscience translational research institute and Kadmon Corporation are also based at the centre.
“A strategic presence in New York City enables more rapid translation of 'bench to bedside' therapies in key areas of oncology, neuroscience, cardiology, immunology, and virology with the result of substantially reducing the economic cost to society of these devastating illnesses," said Joel Marcus, chair and CEO of Alexandria Real Estate Equities.